| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/07/2011 | US20110082190 Nucleic Acids Encoding Anti-IL-12 Antibody |
| 04/07/2011 | US20110082183 Phenyl pyrrole aminoguanidine derivatives |
| 04/07/2011 | US20110082177 N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases |
| 04/07/2011 | US20110082176 Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases |
| 04/07/2011 | US20110082164 Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| 04/07/2011 | US20110082159 METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE |
| 04/07/2011 | US20110082157 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds |
| 04/07/2011 | US20110082156 Fatty acid acipimox derivatives and their uses |
| 04/07/2011 | US20110082153 Gamma secretase modulators |
| 04/07/2011 | US20110082151 Sulfonylurea modulators of endothelin receptor |
| 04/07/2011 | US20110082149 Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation |
| 04/07/2011 | US20110082141 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| 04/07/2011 | US20110082139 Substituted 8-[6-amino-3-pyridyl]xanthines |
| 04/07/2011 | US20110082135 Inhibitors of akt activity |
| 04/07/2011 | US20110082133 Pyridone compounds |
| 04/07/2011 | US20110082129 Organic compounds |
| 04/07/2011 | US20110082120 Substituted thioacetic acid salicylate derivatives and their uses |
| 04/07/2011 | US20110082116 Novel compounds as cannabinoid receptor ligands |
| 04/07/2011 | US20110082114 Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors |
| 04/07/2011 | US20110082113 Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity |
| 04/07/2011 | US20110082110 Water-soluble benzoazepine compound and its pharmaceutical composition |
| 04/07/2011 | US20110082109 Novel acyl guanidine derivatives |
| 04/07/2011 | US20110082108 Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes |
| 04/07/2011 | US20110082099 Methods and Compositions for the Treatment of Cystic Fibrosis and Related Illnesses |
| 04/07/2011 | US20110082085 Peptides derived from the c2 domain of epsilon pkc and methods of use, thereof |
| 04/07/2011 | US20110082084 Methods for the prevention or treatment of heart failure |
| 04/07/2011 | US20110082080 Compositions and methods of using the human proislet peptide receptor |
| 04/07/2011 | US20110082079 Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| 04/07/2011 | US20110081428 Use of thioflavin-like compounds to increase life span and/or health span |
| 04/07/2011 | US20110081427 Nitroxyl Progenitors in the Treatment of Heart Failure |
| 04/07/2011 | US20110081423 Tissue Stabilization for Heart Failure |
| 04/07/2011 | US20110081421 Methods of regulating renalase (monoamine oxidase c) |
| 04/07/2011 | US20110081399 Surface modification of nitinol |
| 04/07/2011 | US20110081371 Angiotensin peptide-carrier conjugates and uses thereof |
| 04/07/2011 | US20110081364 Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
| 04/07/2011 | US20110081360 Human G-Protein Chemokine Receptor (CCR5) HDGNR10 |
| 04/07/2011 | US20110081355 Methods of Diagnosing and Treating Conditions Using Anti-IL-6 Antibodies |
| 04/07/2011 | US20110081337 Function of gpr4 in vascular inflammatory response to acidosis and related methods |
| 04/07/2011 | US20110081325 Novel treatment of heart diseases |
| 04/07/2011 | US20110081323 Methods and compositions for organ and tissue functionality |
| 04/07/2011 | US20110081319 Composition and use of phyto-percolate for treatment of disease |
| 04/07/2011 | US20110081293 Methods and compositions related to clot-binding lipid compounds |
| 04/07/2011 | DE102009042459A1 Composition, useful for the treatment and prophylaxis of diseases of the liver, cardiovascular disease, dementia and Alzheimer's disease, comprises colloidal silver, gold and/or platinum and a choline-containing phosphoglyceride |
| 04/07/2011 | CA2781276A1 Heteroatom containing substituted fatty acids |
| 04/07/2011 | CA2775309A1 Novel phenol derivative |
| 04/07/2011 | CA2774389A1 Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors |
| 04/06/2011 | EP2305822A2 Methods and compositions for diseases associated with Amyloidosis |
| 04/06/2011 | EP2305810A1 miRNAs in the treatment of fibrosis |
| 04/06/2011 | EP2305795A1 Method of collecting placental stem cells |
| 04/06/2011 | EP2305713A1 Human antibodies that bind human TNFalpha |
| 04/06/2011 | EP2305712A1 Human antibodies that bind human TNFalpha |
| 04/06/2011 | EP2305708A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 04/06/2011 | EP2305707A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 04/06/2011 | EP2305706A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 04/06/2011 | EP2305684A1 Poycyloalkylpurines as adenosine receptor antagonists |
| 04/06/2011 | EP2305679A1 Pyrazoline dione derivatives as nadph oxidase inhibitors |
| 04/06/2011 | EP2305678A1 Tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidines as antagonists of serotonin 5-ht6 receptors, methods for the production and use thereof |
| 04/06/2011 | EP2305677A1 Alkyne-aryl-naphthyridin-4(1h)-one derivatives as type IV phosphodiesterase inhibitor |
| 04/06/2011 | EP2305648A1 Amide derivatives useful as glucokinase activators |
| 04/06/2011 | EP2305635A2 Formoterol tartrate process and polymorph |
| 04/06/2011 | EP2305633A1 Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative and use of the pharmaceutical composition |
| 04/06/2011 | EP2305285A1 Means and methods for treating ischemic conditions |
| 04/06/2011 | EP2305276A2 Processed lipoaspirate cells for use in therapy |
| 04/06/2011 | EP2305236A1 Means of Ascertaining an Individual's Risk Profile for Atherosclerotic Disease |
| 04/06/2011 | EP2305235A1 Means of ascertaining an individual's risk profile for atherosclerotic disease |
| 04/06/2011 | EP2305233A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 04/06/2011 | EP2305232A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 04/06/2011 | EP2305231A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 04/06/2011 | EP2305225A1 Use of (1S, 2R) enantiomer of milnacipran for the preparation of a medicine |
| 04/06/2011 | EP2305217A1 Method for the preparation of pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors |
| 04/06/2011 | EP2304049A1 Method of treatment of vascular complications |
| 04/06/2011 | EP2303883A1 Purine derivatives further comprising a mercapto-acylamino group as neutral endopeptidase inhibitors |
| 04/06/2011 | EP2303878A1 Aza-indoles and related compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
| 04/06/2011 | EP2303853A2 Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents |
| 04/06/2011 | EP2303846A1 Substituted isoquinolines and isoquinolinones as rho kinase inhibitors |
| 04/06/2011 | EP2303845A2 Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors |
| 04/06/2011 | EP2303842A1 A process for producing lercanidipine hc1 form v |
| 04/06/2011 | EP2303831A2 Solid states of aliskiren free base |
| 04/06/2011 | EP2303336A2 Sulfonylurea receptor and means for treating ischaemia |
| 04/06/2011 | EP2303313A2 Exendins to lower cholestrol and triglycerides |
| 04/06/2011 | EP2303310A2 Compositions and methods for using cells to treat heart tissue |
| 04/06/2011 | EP2303307A2 Recombinant preparation of bromelain inhibitors and bromelain inhibitor precursor |
| 04/06/2011 | EP2303305A2 Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling |
| 04/06/2011 | EP2303292A1 Compositions comprising cardiac stem cells overexpressing specific micrornas and methods of their use in repairing damaged myocardium |
| 04/06/2011 | EP2303270A1 Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
| 04/06/2011 | EP2303264A1 Methods of treating alpha adrenergic mediated conditions |
| 04/06/2011 | EP2303259A1 Dronedarone for the prevention of cardioversion |
| 04/06/2011 | EP2303251A1 New combination for use in the treatment of inflammatory disorders |
| 04/06/2011 | EP2303249A2 Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions |
| 04/06/2011 | EP2303030A1 Lactobacillus helveticus strains for producing hypotensive peptides |
| 04/06/2011 | EP2000473B1 Trehalose compound and pharmaceutical comprising the compound |
| 04/06/2011 | EP1878431B1 Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues |
| 04/06/2011 | EP1857107B1 Preventive or therapeutic agent for cardiac dysfunction or myocardial damage caused by ischemia or ischemia-reperfusion |
| 04/06/2011 | EP1685832B1 Nerve regeneration promoters |
| 04/06/2011 | EP1628968B1 4-imidazolin-2-one compounds |
| 04/06/2011 | EP1602660B1 Aminophosphonic acid derivatives, addition salts thereof and s1p receptor modulators |
| 04/06/2011 | EP1467749B1 Thrombin derived peptides for promoting cardiac tissue repair |
| 04/06/2011 | EP1407030B1 Methods for large scale production of recombinant dna-derived tpa or k2s molecules |
| 04/06/2011 | EP1255556B1 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 04/06/2011 | CN1993119B Composition containing statins and omega-3 fatty acids |